

# Infection & Chemotherapy

## Manuscript Preparation Instructions

February 2003  
August 2005 (1st Revision)  
July 2008 (2nd Revision)  
February 2010 (3rd Revision)  
December 2012 (4th Revision)  
January 2016 (5th Revision)  
April 2017 (6th Revision)

About the Journal  
Article Type Specifications  
Submission  
Editorial and Peer review process  
Article Types  
Manuscript format and structure  
Manuscript details  
Journal copyediting style

Figures and Illustrations  
How to Submit  
Author's Manuscript Checklist  
Cost  
Copyright and License  
Proofs  
Ethical considerations  
Copyright Transfer Form

## ABOUT THE JOURNAL

### Aims and Scope

*Infection & Chemotherapy (Infect Chemother)* is an international, peer-reviewed, and open-access journal in English, which publishes the current research on issues posed by infectious diseases worldwide. This journal, which is published quarterly (on the last day of March, June, September, and December) in both print and online (<http://www.icjournal.org>) versions, is the only official publication of the Korean Society of Infectious Diseases and Korean Society for Chemotherapy. It publishes review articles, original articles, brief communications, correspondences, case reports, editorials, and special articles covering an extensive range of clinical descriptions on infectious diseases, public health issues, microbiology including emerging resistance, parasitology and immunity to microbes, current and novel treatments, and the promotion of optimal practices or guidelines for diagnoses and treatments.

As the world continues to shrink as a result of globalization, it is necessary that appropriate communication is maintained among countries for timely sharing of information on infectious diseases. This is an important topic because such diseases tend to have unique biologic features according to the regions in which they develop, and these diseases can easily become niduses that may spread globally at any time. Based on these factors, the aim of this publication is to facilitate communication among societies and countries, enabling the worldwide sharing of information on infectious diseases. The scope

of this journal is to link basic and clinical research in the field of infectious diseases, in reference to relevant evidence. The journal continuously attempts to publish current global and regional topics concerning infectious diseases and their diagnoses and managements to create awareness of related issues and link various developing and developed countries.

### Journal Details

Editor-in-Chief, Dong-Gun Lee

#### Editorial office

*Infection & Chemotherapy* #806, Seocho Town Trapalace  
23 Seocho-daero 74-gil, Seocho-gu, Seoul 06621, Korea  
Tel: +82-2-532-6003; Fax: +82-2-535-2494  
E-mail: [ksinfect@naver.com](mailto:ksinfect@naver.com)

### Indexed in

Emerging Sources Citation Index (ESCI)  
PubMed  
PubMed Central  
SCOPUS  
CrossRef and DOI  
DOAJ  
EMBASE  
CAS  
Google Scholar  
CABI  
KoreaMed  
Synapse  
KoMCI

## ARTICLE TYPE SPECIFICATIONS

ARTICLE DESCRIPTION	ABSTRACT	WORD LIMIT	TABLES/FIGURES	REFERENCES
<p><b>Review Article</b> Review articles are usually solicited by the Editor-in-Chief. Authors should contact the Editor-in-Chief in advance to determine the appropriateness of any proposed review. Review topics should be related to clinical aspects of infectious diseases and should reflect trends and progress or a synthesis of data.</p>	Up to 200 words, unstructured	6,500 words (excluding the abstract, reference, and figure/table legends)	Data in the text should not be repeated extensively in tables or figures	100 or less
<p><b>Original article</b> Report clinically relevant investigations or observations within <i>Infection &amp; Chemotherapy</i> scope of interests.</p>	Up to 400 words, structured using the headings Background, Materials and Methods, Results and Conclusion	5,500 words (excluding the abstract, reference, and figure/table legends)	Data in the text should not be repeated extensively in tables or figures	40 or less
<p><b>Brief Communication</b> Brief communications are short original research articles on issues important to medical researchers.</p>	Up to 100 words, unstructured	1,500 words	Max of 3	20 or less
<p><b>Correspondence</b> Letters to the Editor should respond to a recently published article in <i>Infection &amp; Chemotherapy</i> or address an issue of interest to <i>Infection &amp; Chemotherapy</i> readers. Replies will be published in the same issue as the letter, and are invited at the discretion of the Editor.</p>	No abstract required	500 words	Max of 1	10 or less
<p><b>Case Report</b> Case reports should present unusual aspects of common problems or novel perspectives upon, or solutions to, clinically relevant issues.</p>	Up to 400 words, unstructured	2,000 words (excluding the abstract, reference, and figure/table legends)	Data in the text should not be repeated extensively in tables or figures	20 or less
<p><b>Editorial</b> Editorials relate to articles published in <i>Infection &amp; Chemotherapy</i> and are invited at the discretion of the Editor.</p>	No abstract required	1,200 words	Max of 1	10 or less
<p><b>Special Article</b> Special articles are invited with an intention for special introduction of medical issues and any interesting information such as practice guideline.</p>	Up to 200 words, unstructured	6,500 words (excluding the abstract, reference, and figure/table legends)	Data in the text should not be repeated extensively in tables or figures	100 or less

## SUBMISSION

Please read these instructions carefully and follow them closely to ensure that the review and publication of your paper is as efficient and quick as possible. The Editors reserve the right to return manuscripts that are not in accordance with these instructions.

All material to be considered for publication in *Infect Chemother* should be submitted in electronic form via the journal's online submission system at <http://submit.icjournal.org>.

### Cover Letter

The cover letter must include the completed contact information [addresses, telephone and fax numbers, and e-mail] for the corresponding author. The letter should warrant that all authors have seen and approved the manuscript, contributed significantly to the work, and also that the manuscript has not been previously published nor is not being considered for publication elsewhere.

### Related Manuscripts

A copy should be included of any closely related manuscript submitted to or published in *Infect Chemother* or elsewhere, as noted in the journal's Duplicate Publication Policy.

### Permissions

Written permission should be obtained to adapt a part of or reprint an entire table, graph, or illustration that has been previously published. Authors are responsible for obtaining permission from the copyright holder to use copyrighted material prior to submission, and are responsible for paying any associated fees.

## EDITORIAL AND PEER REVIEW PROCESS

*Infect Chemother* reviews all manuscripts received. A manuscript is first reviewed for its format and then sent to the most relevant investigators available for review of the contents. The editor selects peer referees by recommendation of the Editorial Board members or from the Board's specialist database. In addition, if deemed necessary, a review of statistics may be requested. Authors' names and affiliations are removed during peer review, and also the authors realize that the identities of the reviewers are kept confidential.

Acceptance of the manuscript is decided based on the critiques and recommended decision of the referees. A referee may recommend "Accept without revision", "Accept with minor revision", "Major revision", or "Reject". If there is a marked discrepancy in the decisions

between two referees or between the opinions of the author and referee (s), the Editor may send the manuscript to another referee for additional comments and a recommended decision. Three repeated decisions of "review again after revision" are regarded as a "rejection". The reviewed manuscripts are returned back to the corresponding author with comments and recommended revisions. Names and decisions of the referees are masked. A final decision on acceptance for publication or rejection for publication is forwarded to the corresponding author from the Editorial Office.

The usual reasons for rejection are topics that are too specific and target an audience that is too limited, insufficient originality, serious scientific flaws, poor quality of illustrations, or absence of a message that might be important to readers. Rarity of a disease condition is itself not an acceptable justification for a case report. The peer review process takes usually four to eight weeks after the manuscript submission.

Revisions are usually requested to take account of criticisms and comments made by referees. The revised manuscript should be resubmitted via the web system. Failure to resubmit the revised manuscript within 2 months without any notice from the corresponding author is regarded as a withdrawal. The corresponding author must indicate clearly what alterations have been made in response to the referee's comments point by point. Acceptable reasons should be given for non-compliance with any recommendation of the referees.

## ARTICLE TYPES

### Review Article

Review articles are usually solicited by the Editor-in-Chief. Authors should contact the Editor-in-Chief in advance to determine the appropriateness of any proposed review.

Format guide:

- Word limit: 6,500 words (excluding the abstract)
- References: 100 or less
- Abstract: Up to 200 words, unstructured
- Tables/Figures: Data in the text should not be repeated extensively in tables or figures
- Consult the editorial office when reference and word additions are required

### Original Article

Report clinically relevant investigations or observations within *Infect Chemother* scope of interests.

Format guide:

- Word limit: 5,500 words (excluding the abstract)

- References: 40 or less
- Abstract: Up to 400 words, structured using the headings Background, Materials and Methods, Results and Conclusion
- Tables/Figures: Data in the text should not be repeated extensively in tables or figures

### **Brief communication**

Brief communications are short original research articles on issues important to medical researchers.

Format guide:

- Word limit: 1,500 words
- Abstract: Up to 100 words, unstructured
- Tables/Figures: A maximum of 3 figure or table
- References: 20 or less
- No subheadings

### **Correspondence**

Letters to the Editor should respond to a recently published article in *Infect Chemother* or address an issue of interest to *Infect Chemother* readers. Replies will be published in the same issue as the letter, and are invited at the discretion of the Editor.

Format guide:

- Word limit: 500 words
- Tables/Figures: A maximum of 1 figure or table
- References: 10 or less
- No subheadings
- Begin with 'Dear Editor'

### **Case Report**

Case reports should present unusual aspects of common problems or novel perspectives upon, or solutions to, clinically relevant issues.

Format guide:

- Word limit: 2,000 words (excluding the abstract)
- References: 20 or less
- Abstract: Up to 400 words, unstructured
- Tables/Figures: Data in the text should not be repeated extensively in tables or figures

### **Editorial**

Editorials relate to articles published in *Infect Chemother* and are invited at the discretion of the Editor.

Format guide:

- Word limit: 1,200 words
- Tables/Figures: A maximum of 1 figure or table
- References: 10 or less
- Ensure that there is a clear message in the conclusion

### **Special Article**

Special articles are invited with an intention for special introduction of medical issues and any interesting infor-

mation such as practice guideline.

Format guide:

- Word limit: 6,500 words (excluding the abstract)
- References: 100 or less
- Abstract: Up to 200 words, unstructured
- Tables/Figures: Data in the text should not be repeated extensively in tables or figures
- Consult the editorial office when reference and word additions are required

## **MANUSCRIPT FORMAT AND STRUCTURE**

Please refer to a recent issue of *Infect Chemother* for guidance on style and layout of articles. Also refer to the Article type section for guidance on relevant information for each article type.

### **File Formats**

The preferred format for submitting manuscripts online is Microsoft Word (.doc files). PDF files are not acceptable for submission.

### **File Contents**

Manuscript submissions are preferred as a single file, except for figures, which can be uploaded separately. You must also submit a cover letter in a second file, in the same format as your main file.

### **Manuscript Preparation**

Manuscripts should be double-spaced throughout, including the references and the table and figure legends. All pages, except for the figures, should be numbered in the lower right-hand corner of the page, with the title page as page 1. All line numbers should be written in Arabic numerals continuously from the beginning in the abstract. The recommended layout is as follows: title page, abstract, text, acknowledgments, references, tables, figure legends.

The manuscript should be prepared according to the "ICMJE Recommendations for the Conducts, Reporting, and Publication of Scholarly Work in Medical Journals" (2016) (<http://www.icmje.org>). In addition to the ICMJE recommendation, a number of reporting guidelines have been developed by groups of experts to facilitate reporting of research studies or clinical trials (<http://www.equator-network.org/library/>). For reporting of randomized controlled trials, *Infect Chemother* requires compliance with the statement of CONSORT (<http://www.consort-statement.org/>) and the ICMJE Statement on Data Sharing (<http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration>).

- **Title page**
- **Abstract**
- **Key words**
- **Text**
- **Funding**
- **Acknowledgements**
- **References**
- **Tables**
- **Figure Legends**

### **Title Page**

All manuscripts, including Correspondence, should have a title page that includes the following information:

1. A concise, informative title. It is recommended to be less than 150 characters.
2. The names and affiliations of all authors.
3. A running title of less than 50 characters.
4. The complete contact information for the corresponding author.

Title should be concise and precise. Title should provide a reasonable indication of the contents of paper. Avoid the main title/subtitle arrangement, complete sentences, and unnecessary article.

Any changes of address may be given next to the Affiliations or in the Acknowledgments. Any deletions or additions to the author list after submission of the paper must be submitted in writing, and signed by all authors.

### **Abstract**

The second file of the manuscript should contain the Abstract. Please refer to the Article Type for Abstract formats. The Abstract should be comprehensible to readers before they have read the paper and should not contain reference citations.

Original article abstract must be organized and formatted according to the following headings: (1) Background; (2) Materials and Methods; (3) Results; and (4) Conclusion.

It is not necessary to have a fully structured abstract for Review article, Brief communications, Case reports, and Special article.

### **Key words**

Up to five key words should be listed at the end of the abstract to be used as index terms. For the selection of key words, refer to Medical Subject Headings (MeSH) at <http://www.nlm.nih.gov/mesh/MBrowser.html>.

### **Text**

Authors are encouraged to follow the Uniform Require-

ments for Manuscripts Submitted to Biomedical Journals. They should strive for a concise article without excessive detail (word limits are specified under Categories of Articles). All but the shortest articles should have subheadings.

### **Funding**

Details of all funding sources for the work in question should be given in a separate section entitled "Funding." This should appear before the "Acknowledgment" section. The following rules should be followed:

- The sentence should begin: "This work was supported by ..."
- The full official funding agency name should be given, *i.e.* "the National Cancer Institute at the National Institutes of Health" or simply "National Institutes of Health" not "NCI" (one of the 27 subinstitutions) or "NCI at NIH."
- Grant numbers should be complete and accurate and provided in brackets as follows: "[grant number ABX CDXXXXXX]"
- Multiple grant numbers should be separated by a comma as follows: "[grant numbers ABX CDXXXXXX, EFX GHXXXXXX]"
- Agencies should be separated by a semi-colon (plus "and" before the last funding agency)
- Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number "to [author initials]."

An example is given here: "This work was supported by Korea Centers for Diseases Control and Prevention".

### **Acknowledgement**

Personal acknowledgment should precede those of institutions of agencies. Any substantial assistance in preparing the manuscript—for example, in data retrieval or statistical analysis—other than by an author should be stated.

Please note that acknowledgment of funding bodies and declarations regarding conflicts of interest should be given in separate Funding and Conflicts of Interest sections, respectively.

### **References**

Names of journals are abbreviated according to the List of Journals Indexed for Medline. Titles of journals not listed in Medline should be spelled out in full. References should be numbered consecutively as they appear in the text, with the numbers in brackets on the text line (*e.g.*, [3, 7–9, 57]). Reference to a doctoral dissertation should include the author, title, institution, location, year, and publication information, if published. For online resources, a URL and date accessed should be included. Accuracy of references

is the responsibility of the authors.

The citation of journals, books, multi-author books, and articles published online should conform to the following examples:

#### Journals

- Pittet D, Wenzel RP. Nosocomial bloodstream infections: secular trends in rates, mortality, and contribution to total hospital deaths. *Arch Intern Med* 1995;155:1177-84.
- Centers for Disease Control and Prevention (CDC). Revised classification system for HIV infection in children less than 13 years of age. *MMWR Morb Mortal Wkly Rep* 1994;43:1-10.
- Chen SA. AF News. *J Cardiovasc Electrophysiol* 2016 [Epub ahead of print]
- Shen HM, Zhang QF. Risk assessment of nickel carcinogenicity and occupational lung cancer. *Environ Health Perspect* 1994;102 (Suppl 1):S275-82.

#### Books

- Seah AI, Hornick RB. *Principles and Practice of Infectious Diseases*. 2nd ed. New York: Wiley Medical; 1985;1094
- Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, eds. *Hypertension: pathophysiology, diagnosis, and management*. 2nd ed. New York: Raven Press; 1995;465-78.

#### Website

- Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available at: <http://www.aidsinfo.nih.org>. Accessed 24 April 2002.

#### Tables

All tables should be on separate pages and accompanied by a title, and footnotes where necessary. The tables should be numbered consecutively using Arabic numerals. Units in which results are expressed should be given in parentheses at the top of each column and not repeated in each line of the table. Ditto signs are not used. Avoid overcrowding the tables and excessive words. The format of tables should be in keeping with that normally used by the journal; in particular, vertical lines, colored texts, and shading should not be used. Be certain that the data given in tables are correct.

In a footnote to the table, all abbreviations used should be defined, unless otherwise defined in the text, excluding units of measure. Footnotes and accompanying explanatory material should be kept to a minimum. Foot-

notes should be placed below the table and designated by superscript lowercase letters (listed in order of location when the table is read horizontally). Each column must have a heading describing the data below, and units of measure must be clearly indicated for all data.

#### Figure Legends

These should be on a separate, numbered manuscript sheet. Define all symbols and abbreviations used in the figure. Figures and legends should be intelligible without reading the text of the manuscript.

## MANUSCRIPT DETAILS

#### Nomenclature

*Infect Chemother* attempts to use the latest widely accepted nomenclature. See Bergey's Manual of Determinative Bacteriology (9th ed., revised, Williams & Wilkins, 1994) and Enzyme Nomenclature: Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the Nomenclature and Classification of Enzymes (Academic Press, 1992). Formal terms for virus families, genera, and species should be those approved by the International Committee on Taxonomy of Viruses; see Virus Taxonomy—The Classification and Nomenclature of Viruses: Seventh Report of the International Committee on Taxonomy of Viruses (Academic Press, 2000). This volume also includes standard abbreviations for virus species. For names and abbreviations of chemical compounds, refer to the Merck Index (13th ed., Merck, 2001). The Editors appreciate the assistance of authors and readers who inform them of changes in nomenclature.

#### Human Genetic Nomenclature and Notation

For human genes, use genetic notation and symbols approved by the Human Gene Mapping Workshop (see Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, Povey S. Guidelines for human gene nomenclature. *Genomics* 2002; 79:464-70). Human gene names and loci should be written in italicized capital letters and Arabic numerals. Human protein product names are not italicized. For human mutation nomenclature, see Antonarakis *et al.* (Recommendations for a nomenclature system for human gene mutations. *Hum Mutat* 1998; 11:1-3).

#### Human Single-Nucleotide Polymorphisms (SNPs)

For human genes, newly described SNPs should be submitted to an appropriate database, such as dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/>), prior to submission of the revised manuscript. The identification numbers of previously recognized SNPs (rs numbers) or recently

submitted SNPs (ss numbers) should be provided in the manuscript, if the number of SNPs is small, or submitted as supplemental online material, if the number is large.

### Statistical analysis

The statistical analyses used should be identified both in the text and in all tables and figures where the results of statistical comparison are shown.

### Units of measurement

The use of SI units is encouraged. All data should be expressed in metric units. Temperature should be expressed in degrees Celsius.

### Abbreviations

Non-standard abbreviations should be kept to a minimum. They should be defined at the first occurrence and introduced only where multiple use is made.

**Drugs and pharmaceutical agents.** Should an author decide to abbreviate the names of antimicrobial agents in a manuscript, the following standard abbreviations are strongly recommended.

Please check the website (<http://www.ksac.or.kr/medical/sub05.html>) for more details, and refer to the previous version of the website for abbreviations that are not included in the third version.

(i) **Antibacterial agents.** Use the indicated abbreviations for the following antibacterial agents.

amikacin	AMK
amoxicillin	AMX
amoxicillin-clavulanic acid	AMC
ampicillin	AMP
ampicillin-sulbactam	SAM
arbekacin	ABK
azithromycin	AZM
azlocillin	AZL
aztreonam	ATM
capreomycin	CPM
carbenicillin	CAR
cefaclor	CEC
cefadroxil	CFR
cefoperazone/sulbactam	SCF
cefamandole	FAM
cefazolin	CFZ
cefdinir	CDR
cefditoren	CDN
cefepime	FEP
cefetamet	FET
cefixime	CFM
cefmetazole	CMZ
cefonicid	CID
cefoperazone	CFP

cefotaxime	CTX
cefotetan	CTT
cefoxitin	FOX
cefpodoxime	CPD
cefprozil	CPR
ceftazidime	CAZ
ceftibuten	CTB
ceftizoxime	ZOX
ceftriaxone	CRO
cefuroxime (axetil or sodium)	CXM
cephalexin	LEX
cephalothin	CEF
cephapirin	HAP
cephradine	RAD
chloramphenicol	CHL
ciprofloxacin	CIP
clarithromycin	CLR
clinafloxacin	CLX
clindamycin	CLI
colistin	CST
cycloserine	CCS
daptomycin	DAP
dirithromycin	DTM
doxycycline	DOX
erythromycin	ERY
ethambutol	ETB
ethionamide	EA
fosfomycin	FOF
gemifloxacin	GEM
gentamicin	GEN
imipenem	IPM
isoniazid	INH
kanamycin	KAN
levofloxacin	LVX
linezolid	LZD
lomefloxacin	LOM
meropenem	MEM
methicillin	MET
metronidazole	MDZ
minocycline	MIN
moxifloxacin	MXF
nafcillin	NAF
nalidixic acid	NAL
netilmicin	NET
nitrofurantoin	NIT
norfloxacin	NOR
ofloxacin	OFX
oritavancin	ORI
oxacillin	OXA
p-aminosalicylic acid	PAS
penicillin	PEN
piperacillin	PIP
piperacillin-tazobactam	TZP

polymyxin B	PMB
prothionamide	PTH
oyrazinamide	PZA
rifabutin	RFB
rifampin (rifampicin)	RIF
rifamycin	RF
rifapentin	RFP
streptomycin	STR
teicoplanin	TEC
telithromycin	TEL
tetracycline	TET
ticarcillin	TIC
ticarcillin-clavulanic acid	TIM
tigecycline	TGC
tobramycin	TOB
trimethoprim-sulfamethoxazole	TMP/SMX
vancomycin	VAN

(ii) **Antifungal agents.** Use the indicated abbreviations for the following antifungal agents.

amphotericin B deoxycholate	AMB
anidulafungin	ANF
caspofungin	CAF
clotrimazole	CLT
fluconazole	FLC
flucytosine	5FC
itraconazole	ITC
ketoconazole	KTC
liposomal amphotericin B	LAB
micafungin	MIF
nystatin	NYT
posaconazole	PSC
terbinafine	TRB
voriconazole	VRC

(iii) **Antiviral agents.** Use the indicated abbreviations for the following antiviral agents.

abacavir	ABC
acyclovir	ACV
adefovir	ADV
atazanavir	ATV
cidofovir	CDV
cobicistat	COBI
darunavir	DRV
didanosine	ddI
dolutegravir	DTG
efavirenz	EFV
elvitegravir	EVG
emtricitabine	FTC
enfuvirtide	T20
entecavir	ETV
etravirine	ETR

famciclovir	FCV
foscarnet	FOS
ganciclovir	GCV
indinavir	IDV
lamivudine	3TC
lopinavir	LPV
maraviroc	MVC
nelfinavir	NFV
nevirapine	NVP
raltegravir	RAL
ribavirin	RBV
rilpivirine	RPV
ritonavir	RTV
ritonavir-boosted atazanavir	ATV/r
ritonavir-boosted darunavir	DRV/r
ritonavir-boosted lopinavir	LPV/r
ritonavir-boosted tipranavir	TPV/r
stavudine	d4T
tenofovir disproxil fumarate	TDF
tipranavir	TPV
valaciclovir	VACV
valganciclovir	VGCV
zidovudine	ZDV

(iv) **Others.** Use the indicated abbreviations for the following others.

albendazole	ADZ
artemether	AMET
artemisinin	AMS
artesunate	AS
atovaquone	AT
atovaquone/proguanil	AT/PGU
chloroquine	CQ
mebendazole	MBDZ
mefloquine	MQ
nitazoxamide	NTZX
paromomycin	PRM
pentamidine	PTMD
praziquantel	PZQT
primaquine	PQ
pyrimethamine	PM
quinine	QN

## JOURNAL COPYEDITING STYLE

Authors are referred to the *AMA Manual of Style: A Guide for Authors and Editors* (10th ed., Oxford University Press, 2007) and the *Chicago Manual of Style* (16th ed., University of Chicago Press, 2010). For commercially obtained products mentioned in the text, the full names of manufacturers should be listed. Generic names of drugs and other chemical compounds should be used.

## FIGURES AND ILLUSTRATIONS

Figures should also be numbered in the order of mention in the text and should appear at the end of the manuscript and references. Figures will not be relettered by the publisher. The journal reserves the right to reduce the size of illustrative material.

### Formatting

Multipart figures should be submitted as a single file, with panels labeled within the image, rather than as multiple files. Letters, numbers, and symbols should be clear and of sufficient size to be legible when the figures are reduced. Photomicrographs should have internal scale markers. If the manuscript is accepted, the author will be required to supply high resolution figure files for production.

Save figure files in TIFF or EPS format, using CMYK colors, with fonts embedded. When creating figures, please make sure any embedded text is large enough to read. If figures contain miniscule characters such as numbers on a chart or graph, they will most likely be illegible in the final version.

For useful information on preparing your figures for publication, go to <http://cpc.cadmus.com/da>.

### Halftone Illustrations, Photographs

Any photomicrographs, electron micrographs, or radiographs must be of high quality with respect to detail, contrast, and fineness of grain to withstand the inevitable loss of contrast and detail inherent in the printing process. Wherever possible, photographs should fit within the print area or within a column width. Photomicrographs should provide details of staining technique and a scale bar. Patients shown in photographs should have their identity concealed or should have given their written consent to publication. Please indicate the magnification by a bar on the photograph. Minimum resolutions are 300 d.p.i for color or tone images.

### Line Drawings

All line drawings should have clear and sharp lines. No additional artwork, redrawing, or typesetting will be done. Therefore, all labeling should be done on the original line drawing. Faint shading and stippling could be lost upon reproduction and should be avoided. Line drawings must have a resolution of at least 600 d.p.i. at their final size.

### Color Illustrations

Authors are required to pay the full cost of reproduction of color figures. For details see *Infect Chemother* charges. If you require color reproduction of figures in the print journal you will be asked to approve the cost.

An invoice will be issued at the time of publication.

*Infect Chemother* also offers free reproduction of color figures in the online version (figures in the print version will appear in black and white). Figure captions must be suitable worded to apply to both the print and online versions of the article.

## HOW TO SUBMIT

### Online Submission

We only accept manuscript submission via our online manuscript submission system (<http://submit.icjournal.org>). Before submitting a manuscript, authors are encouraged to consult both our Editorial Policies and the Manuscript Preparation Instruction for our online manuscript submission system. If you have not already done so, please register for an account with our online manuscript system. You will be able to monitor the status of your manuscript online throughout the editorial process.

### Submission of Revisions

Authors submitting a revised manuscript after review are asked to include the following:

- (1) A rebuttal letter, indicating point-by-point how you have addressed the comments raised by the reviewers. If you disagree with any of the points raised, please provide adequate justification in your letter.
- (2) A marked-up version of the manuscript that highlights changes made in response to the reviewers' comments in order to aid the Editors and reviewers.

## AUTHOR'S MANUSCRIPT CHECKLIST

### Original article

1. Typed double-spaced in 12-point font on A4 and prepared as an electronic file, preferably using Microsoft (MS) Word.
2. Sequence: title page, abstract and keywords, introduction, materials and methods, results, discussion, funding, acknowledgment, references, tables, and figure legends. All pages should be numbered consecutively, starting from the title page.
3. Give line numbers from the beginning in the abstract.
4. Title page with article title (less than 150 characters), authors' full name (s) and affiliation (s), corresponding author (include phone and fax numbers and e-mail address), running title (less than 50 characters), and footnotes, if any.
5. Abstract in structured format within 400 words and up to five key words from MeSH.
6. Total text does not exceed 5,500 words (excluding

- abstract, references, and figure/table legends).
7. All table and figure numbers appear in the text.
  8. References: 40 or less. References are listed in proper format. All listed references are cited in the text, and vice versa.
  9. A cover letter stating that the material has not been published previously and will not be submitted for publication elsewhere and reporting all conflicts of interest for all listed authors.
  10. Human research should be approved by IRB: Its approval or exempt is needed to be written in the manuscript.

You can find the checklist of other manuscripts in online submission system.

## COST

### Submission Charge

No charge for all kinds of manuscripts submitted to our online system.

### English Editing

Papers that will be published since 2014 must go through an English editing process, and for those that do not undergo the editing process will undergo the editing process after permission is granted for publication. The fees will be charged to the author.

### Page Charge

The following applies to papers published since the 1st issue of 2014:

- Original article: No fees for publication
- Case report: US \$200 / KRW 200,000 (4-page basis), additional pages: US \$60/page / KRW 60,000/page
- Color image: US \$100/page / KRW 100,000/page

## COPYRIGHT AND CREATIVE COMMONS ATTRIBUTION LICENSE

It is a condition of publication in *Infect Chemother* that the authors grant an exclusive license to the journal's sponsoring society, the Korean Society of Infectious Diseases and Korean Society for Chemotherapy. They also follow the Creative Commons Attribution Non-Commercial License available from: <http://creativecommons.org/licenses/by-nc/3.0/>. For any commercial use of material from the open access version of the journal, permission must be obtained from the Korean Society of Infectious Diseases and Korean Society for Chemotherapy. This ensures that all of the necessary rights needed for publication of the article are in place including provision for

any requests from third parties to reproduce the content to be as widely disseminated as possible. No article will be published unless the signed license has been received at *Infect Chemother*. On acceptance of your article for publication, the license form should be returned immediately by fax or by sending a scanned PDF copy, and the original must be posted as soon as possible. Faxing a copy of the form when requested will assist in the rapid publication of your article but the Original form should also be returned. Any queries about the license form should be sent as soon as possible to Rights and permissions so that any issues can be resolved quickly and to avoid any delay in publication.

Work submitted for publication must be original, previously unpublished, and not under consideration for publication elsewhere. If previously published figures, tables, or parts of text are to be included, the copyright-holder's permission must have been obtained prior to submission.

Please see Copyright Transfer Form.

## PROOFS

Authors are sent page proofs by e-mail. To avoid delays in publication, proofs should be checked immediately and corrections, as well as answers to any queries, returned to the publishers as an annotated PDF via email or fax within 2 working days. Further details are supplied with the proof. It is the author's responsibility to check proofs thoroughly.

Excessive alterations in the proof stage may delay publication of the article to a subsequent issue. Authors who make extensive amendments to the text at the page-proof stage will be charged an additional fee.

## ETHICAL CONSIDERATIONS

### Research Ethics

All of the manuscripts should be prepared in strict observation of research and publication ethics guidelines recommended by the Council of Science Editors, International Committee of Medical Journal Editors, World Association of Medical Editors, and the Korean Association of Medical Journal Editors. Any study including human subjects or human data must be reviewed and approved by a responsible institutional review board (IRB). Please refer to the principles embodied in the Declaration of Helsinki (<http://www.wma.net/e/policy/b3.htm>) for all investigations involving human materials. Animal

experiments also should be reviewed by an appropriate committee (IACUC) for the care and use of animals. Also studies with pathogens requiring a high degree of biosafety should pass review of a relevant committee (IBC). The editor of *Infect Chemother* may request submission of copies of informed consents from human subjects in clinical studies or IRB approval documents.

### Conflicts of Interest

The corresponding author of an article is asked to inform the Editor of the authors' potential conflicts of interest possibly influencing their interpretation of data. A potential conflict of interest should be disclosed in the cover letter even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems. Disclosure form shall be same with ICMJE Uniform Disclosure Form for Potential Conflicts of Interest ([http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf)). The Editor will decide whether the information on the conflict should be included in the published paper. Before publishing such information, the Editor will consult with the corresponding author. In particular, all sources of funding for a study should be explicitly stated. The *Infect Chemother* asks referees to let its Editor know of any conflict of interest before reviewing a particular manuscript.

- **Funding:** Research support (including salaries, equipment, supplies, reimbursement for attending symposia, and other expenses) by organizations that may gain or lose financially through this publication. The role of the funding body in the design of the study, collection and analysis of data and decision to publish should be stated.
- **Employment:** Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through this publication.
- **Personal financial interests:** Stocks or shares in companies that may gain or lose financially through publication; consultation fees or other forms of remuneration from organizations that may gain or lose financially; patents or patent applications whose value may be affected by publication.

Examples of declarations are:

- Conflicts of interest.  
No conflicts of interest.
- Conflict of interest.

JAM reports grants and personal fees from Bio-Rad, personal fees and non-financial support from Astellas and Basilea, and grants, personal fees and non-financial support from Gilead Sciences, Merck Sharp and

Dohme, and Pfizer, Inc. during the conduct of the study. KAM has a patent (diagnostics for aspergillosis) licensed to MycoMed Technologies. D-GL reports grants and personal fees from Astellas, Gilead Sciences, MSD, Pfizer, and Yuhan, outside the submitted work.

### Authorship

The *Infect Chemother* follows the recommendations for authorship by the International Committee of Medical Journal Editors (ICMJE, <http://www.icmje.org>) and Good Publication Practice Guidelines for Medical Journals 2nd Edition (KAMJE, 2013, [http://kamje.or.kr/data/guide\(2\).pdf](http://kamje.or.kr/data/guide(2).pdf)). Authorship credit should be based on 1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; 2) Drafting the work or revising it critically for important intellectual content; 3) Final approval of the version to be published; and 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors.

When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.

### Correspondence with the Journal

One author is designated the contact author for matters arising from the manuscript (materials requests, technical comments and so on). It is this author's responsibility to inform all co-authors of matters arising and to ensure such matters are dealt with promptly. Before submission, the corresponding author ensures that all authors are included in the author list, its order agreed upon by all authors, and are aware that the manuscript was submitted. After acceptance for publication, proofs are e-mailed to this corresponding author who should circulate the proof to all co-authors and coordinate corrections among them.

### Correction and Retraction Process

Content published as Advance Online Publication (AOP) is final and cannot be amended. The online and print versions are both part of the published record hence the original version must be preserved and changes to the

paper should be made as a formal correction. If an error is noticed in an AOP article, a correction should accompany the article when it publishes in print. An HTML (or full-text) version of the correction will also be created and linked to the original article. If the error is found in an article after print publication the correction will be published online and in the next available print issue.

Please note the following categories of corrections to print and online versions of peer reviewed content:

- **Erratum.** Notification of **an important error made by the journal** that affects the publication record or the scientific integrity of the paper, or the reputation of the authors, or of the journal.
- **Corrigendum.** Notification of **an important error made by the author** that affects the publication record or the scientific integrity of the paper, or the reputation of the authors or the journal.
- **Retraction.** Notification of **invalid results.** All co-authors must sign a retraction specifying the error and stating briefly how the conclusions are affected. Decisions about corrections are made by the Editor (sometimes with peer-reviewers' advice) and this sometimes involves author consultation. Requests to make corrections that do not affect the paper in a significant way or impair the reader's understanding of the contribution (a spelling mistake or grammatical error, for example) are not considered. In cases where co-authors disagree about a correction, the editors will take advice from independent peer-reviewers and impose the appropriate correction, noting the dissenting author(s) in the text of the published version.

### **Redundant Publication and Plagiarism**

Redundant publication is defined as "reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s)". Characteristics of reports that are substantially similar include the following: (a) "at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant publication)," (b) "the subject or study populations

are often the same or similar," (c) "the methodology is typically identical or nearly so," and (d) "the results and their interpretation generally vary little, if at all."


When submitting a manuscript, authors should include a letter informing the editor of any potential overlap with other already published material or material being evaluated for publication and should also state how the manuscript submitted to *Infect Chemother* differs substantially from this other material. If all or part of your patient population was previously reported, this should be mentioned in the Materials and Methods, with citation of the appropriate reference(s).

*Infect Chemother* use CrossCheck, a plagiarism detection software tool, to identify instances of overlapping and similar text in submitted manuscripts. CrossCheck is a multi-publisher initiative to screen published and submitted content for originality. To find out more about CrossCheck visit [www.crossref.org/crosscheck.html](http://www.crossref.org/crosscheck.html).

If a case of plagiarism comes to light after a paper is published, the Journal will conduct a preliminary investigation, utilising the guidelines of the Committee on Publication Ethics. If plagiarism is proven, the Journal will contact the author's institute and funding agencies as appropriate. The paper containing the plagiarism may also be formally retracted or subject to correction.

### **Obligation to Register Clinical Trial**

Clinical trial defined as "any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome" should be registered to the primary registry to be prior publication. *Infect Chemother* accepts the registration in any of the primary registries that participate in the WHO International Clinical Trials Portal (see <http://www.who.int/ictrp/about/details/en/index.html>) as well as [www.actr.org.au](http://www.actr.org.au), [www.clinicaltrials.gov](http://www.clinicaltrials.gov), [www.ISRCTN.org](http://www.ISRCTN.org), [www.umin.ac.jp/ctr/index/htm](http://www.umin.ac.jp/ctr/index/htm) and [www.trialregister.nl](http://www.trialregister.nl). The clinical trial registration number shall be published at the end of the abstract.



# Copyright Transfer Form

---

**Title :** \_\_\_\_\_  
\_\_\_\_\_

**Type :** Review Article \_\_\_\_ • Original Article \_\_\_\_ • Brief communication \_\_\_\_  
Correspondence \_\_\_\_ • Case Report \_\_\_\_ • Editorial \_\_\_\_ • Special Article \_\_\_\_

## 1. Informed Consent

The author(s) haven't suggested any personal information that may make the identity of the patient recognizable in any forms of description part, photograph or pedigree. When the photographs of the patient were essential and indispensable as scientific information, the author(s) have received the consent in writing form and have clearly stated it.

## 2. Human and Animal Right

In case of experimenting on human, the author(s) have certified that the process of the research is in accordance with ethical standards of Helsinki declaration, domestic and foreign committees that preside over human experiment. If any doubts are raised whether the research was proceeded in accordance with the declaration, the author(s) would explain it. In case of experimenting on animals, the author(s) have certified that the author(s) had followed the domestic and foreign guideline related to experiment of animals in a laboratory.

## 3. Copyright Transfer

The author(s) have received consent from the author or editor about the picture or the table that was quoted from other journals or books. A portion or entire of the article hasn't been published on other journals nor contributed to other journals and under review.

The author(s) undersigned hereby transfer all rights, interest, copyright and digital copyright related to the journal to the Korean Society of Infectious Diseases and the Korean Society for Chemotherapy when it is published on Infection and Chemotherapy.

## 4. Disclosure of Conflict of Interest

Author(s) of the journal have clarified everything that interest may arise such as research expenses, consultant expenses, stock, particularly concerned person of the judges on the document of disclosure of conflict of interest.

**Signed :** \_\_\_\_\_ **Date :** \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

